Aftercare hub
After Mounjaro and Wegovy: aftercare, maintenance, and regain
Oliver Mackman · Editorial director · Best Business Loans Ltd (16833937)
Last updated 2026-06-24
Editorial with affiliate links. We earn from purchases via outbound retailer / clinic links. How we are funded.
GLP-1 aftercare is the maintenance phase after stopping prescription weight-loss medication such as Mounjaro or Wegovy. The published evidence is consistent: roughly 82 percent of people regain at least a quarter of lost weight within 12 months of stopping (Oxford analysis, January 2026). Maintenance dose, resistance training and high protein intake reduce regain. PeptideClear is editorial commentary, not clinical advice; whether to taper, maintain or stop is a decision for the reader and a UK-licensed prescriber.
The four phases
Most UK private programmes assume a 12 to 18 month treatment cycle. Many people stop sooner because of cost, supply, or side effects. The phases below are typical, not prescriptive. Your prescriber will adapt.
Active treatment (months 0-12)
Focus: Dose progression, weekly habits, protein, resistance training
Risk: Muscle loss if protein is low. Bone density risk in older women. Plateau is normal.
Goal weight reached (month 12-18 typical)
Focus: Decision: continue at maintenance dose, taper, or stop. Speak with prescriber.
Risk: 95% of clinical-trial participants stayed on medication. Full stop is the highest-regain path.
Tapering (4-12 weeks)
Focus: Stepwise dose reduction. Keep all habits in place. Plan the food environment.
Risk: Hunger returns first. Cravings second. Adapt protein and sleep before the regain starts.
Off medication (month 18+)
Focus: Weight regain risk peaks at months 6-12 off. Re-entry is common and not a failure.
Risk: 82% regain at least 25% of lost weight in the first year off (Oxford analysis, Jan 2026).
What helps regain risk drop
- · Resistance training before, during, and after. Up to half of GLP-1 weight loss is non-fat. Lean mass is the regain insurance.
- · Protein at 1.4 to 1.8g per kg of goal body weight per day. Protein page.
- · A maintenance dose rather than a full stop, if your prescriber agrees and your finances allow. Trial data favours staying on medication.
- · Behaviour scaffolding (food environment, sleep, structured weekly review) before the regain wave hits.
- · Re-entry plan. If regain starts, restarting is normal and not a failure. Speak with your prescriber early, not late.
How to judge a clinic on ongoing support
A common complaint about private GLP-1 routes is thin clinical support after the first prescription: a repeat-supply portal with little human contact. Ongoing support is one of the clearest ways UK clinics and pharmacies differ, and it is worth checking before you commit. Reasonable things to ask:
- · Is there a named clinician or care team you can actually reach, or only a reorder button?
- · How are dose changes reviewed: a clinician check-in, or automatic progression on a fixed timer?
- · What is the response time if you have a side effect or a question mid-treatment?
- · Do they offer a genuine maintenance or tapering pathway, or only continued full-dose supply?
- · Is there practical support on the things that go wrong (a warm delivery, a broken needle, a missed week) with fast replacement?
- · Do they check the basics over time (weight trend, and where appropriate the bloods below) rather than just dispensing?
Aftercare quality is a service decision, not a clinical one we make for you. Compare providers on it the way you would compare on price. See the clinics and pharmacies directories.
Open questions on aftercare in 2026
- · Does NHS Mounjaro have a defined off-ramp? Currently no. NHS treatment is up to two years per the NICE TA1026 commissioning guidance, with no nationally-funded maintenance pathway after.
- · Will Cohort 2 (launching 23 June 2026) get the same time-limited model? Yes, expected.
- · Are private clinics offering true maintenance dosing? Numan and Voy advertise it. Pharmacy-direct routes typically do not pause progression.
- · Does the Wegovy CV outcome indication (approved July 2024) change aftercare? Possibly. People with CV-disease eligibility may be told to stay on medication indefinitely.
Editorial
Baseline panels to track
If you are working with a UK private doctor or NHS prescriber on a peptide protocol, these are the blood panels typically ordered at baseline for GLP-1 medications. Not a recommendation for self-administered testing.
- HbA1c. Baseline plus 12-week follow-up. The canonical metabolic marker tracked across UK NHS and private GLP-1 protocols. Captures glucose impact across a 90-day window.
- Fasting glucose. Baseline establishes pre-treatment glucose handling. Prescribers use this alongside HbA1c to assess whether glucose changes are pharmacologic rather than pre-existing.
- Lipid panel. Weight loss and GLP-1 therapy shift the lipid profile. Baseline lipid panel allows the prescriber to track cardiovascular markers across the treatment cycle.
- Weight and waist circumference. Not a blood panel, but the canonical adjunct measure. Waist circumference tracks visceral adiposity more sensitively than weight alone and is the standard non-invasive metric across UK private programmes.
Order a UK lab panel
Affiliate links to UK lab providers. PeptideClear earns commission on bookings. Editorial selection independent. See how we are funded.
Popular on PeptideClear
Ready to buy
Find a UK GLP-1 clinic or pharmacy
GMC-registered prescribers compared by price, consultation type, and refund policy. Editorial only. We do not prescribe.